The 2013 Pennington Biomedical Research Center's Scientific Symposium focused on the treatment and management of pediatric obesity and was designed to (i) review recent scientific advances in the prevention, clinical treatment and management of pediatric obesity, (ii) integrate the latest published and unpublished findings and (iii) explore how these advances can be integrated into clinical and public health approaches. The symposium provided an overview of important new advances in the field, which led to several recommendations for incorporating the scientific evidence into practice. The science presented covered a range of topics related to pediatric obesity, including the role of genetic differences, epigenetic events influenced by in utero development, pre-pregnancy maternal obesity status, maternal nutrition and maternal weight gain on developmental programming of adiposity in offspring. Finally, the relative merits of a range of various behavioral approaches targeted at pediatric obesity were covered, together with the specific roles of pharmacotherapy and bariatric surgery in pediatric populations. In summary, pediatric obesity is a very challenging problem that is unprecedented in evolutionary terms; one which has the capacity to negate many of the health benefits that have contributed to the increased longevity observed in the developed world.
INTRODUCTION
Pediatric obesity is a major public health problem in developed countries and is also becoming an issue in many developing nations. 1 In addition to being at increased risk of remaining obese as an adult, 2 obese children have lower health-related quality of life, 3, 4 an increased risk of having metabolic disorders and adverse cardiovascular disease risk factors, 5, 6 and a greater chance of psychological and social problems such as being the victim or perpetrator of bullying. 7, 8 The economic and health-care costs associated with pediatric obesity are high and are predicted to rise in the United States unless the prevalence can be reduced through effective prevention and treatment. 9, 10 Pediatric obesity is rarely due to single-gene defects transmitted from parents to offspring or arising de novo. It develops in the presence of complex and generally subtle biological predispositions that become manifest under environmental and social conditions where obesogenic behaviors are adopted. Thus, understanding the additive and multiplicative interactions between obesogenic behaviors and biology on the modulation of adiposity and the risk of pediatric obesity is an urgent public health priority. Consequently, pediatric obesity prevention and treatment can span the continuum from modifications to the policy and built environment, to behavioral and pharmacological interventions and surgical approaches.
On 27-29 October 2013, the Pennington Biomedical Research Center convened a scientific symposium on the scientific basis for the prevention, management and treatment of childhood obesity. The specific objectives of the symposium were to (i) review recent scientific advances in the prevention, clinical treatment and management of pediatric obesity, (ii) integrate the latest published and unpublished findings and (iii) explore how these advances can be integrated into clinical and public health approaches. The scientific program was developed to review both preclinical and clinical data on the genetic, epigenetic and behavioral influences on pediatric obesity such as those observed during gestation and early childhood development. In addition, the relative merits of various behavioral approaches in the treatment of pediatric obesity, and the specific roles of pharmacotherapy and bariatric surgery in pediatric populations were discussed. The purpose of this article is to summarize the evidence discussed and provide recommendations for implementing evidence-based solutions in clinical and public health settings.
EPIDEMIOLOGY OF PEDIATRIC OBESITY AND SEVERE OBESITY
Most population health surveillance systems rely on the body mass index (BMI; kg m -2 ) as an indicator of the presence of overweight or obesity in both adults and children. Among children and adolescents, cutoff criteria are typically based on national or international pediatric reference data. For example, the World Health Organization has published growth standards for infants and children from birth to 5 years of age 11 and growth reference curves for BMI for children 5-19 years of age. 12 Similarly, using an international sample of children and adolescents, the International Obesity Task Force produced BMI growth curves using least median of squares (LMS) regression set to adult overweight (25 kg m -2 ) and obesity thresholds (30 kg m -2 ) at 18 years of age. 13 These reference curves were recently updated to include thresholds for underweight. 14 In the United States, the most commonly used reference data are the Centers for Disease Control and Prevention (CDC) BMI growth charts, 15 and children and adolescents are considered overweight if their BMI is ⩾ 85th percentile and obese if their BMI is ⩾ 95th percentile. In addition, more severe or extreme levels of pediatric obesity have been defined using the 97th and 99th percentiles, or 120% of the 95th percentile. [16] [17] [18] The global prevalence of pediatric obesity increased considerably in recent decades and remains high 1, 19 In the United States, the prevalence of obesity among children and adolescents increased from 5% in 1971-1974 to 16 .9% in 2009-2010. 16, 20 The prevalence of obesity has increased in all age groups, but the rise in 2-to 5-year old has not been as great as in older children and adolescents ( Figure 1a ). Despite the rapid and significant increase in pediatric obesity since the 1970s, there is some evidence that the prevalence may be stabilizing in some countries. For example, an analysis of data collected between 1995 and 2008 from nine countries (Australia, China, England, France, The Netherlands, New Zealand, Sweden, Switzerland and the United States) demonstrated that the rate of change in obesity over that time frame was -0.01%. 21 In addition to the observed increases in overall obesity prevalence, more severe forms of pediatric obesity have also increased, possibly at a greater rate. For example, between 1971-1974 and 2009-2010 , the prevalence of pediatric obesity increased 3.3-fold; 16, 20 whereas for severe pediatric obesity this rose 4-fold between 1976-1980 and 1999-2006 . 18 Similar to the trends in overall obesity, severe obesity has increased at a slower rate among 2-to 5-year-old children compared with older children and adolescents (Figure 1b) . Conversely, comparable to reported trends of a plateauing of overall pediatric obesity prevalence, a recent study has indicated that extreme obesity in pre-school children increased between 1998 and 2003 but then declined from 2003 to 2010. 22 In summary, the epidemiological evidence indicates that pediatric obesity and severe obesity has increased substantially in recent decades. Although there is some evidence that the increases may be slowing in recent years, the prevalence remains historically high.
THE HUMAN GENOME: ONE OF THE DRIVERS OF PEDIATRIC OBESITY Two decades of research on the nature of the conditions that led to the obesity epidemic have allowed us to conclude that there are multiple social, environmental, behavioral and biological determinants of what has been termed 'a constellation of obesogenic conditions.' These determinants exhibit not only statistically significant main effects but also interactive and multiplicative influences on the risk of gaining weight and becoming obese. Although there are a few exceptions, an important property of most of these determinants is that, when taken individually, they generally are characterized by small effect sizes.
The genetic component of obesity arises mainly as a function of DNA sequence differences and other genomic features such as chromosomal anomalies. Furthermore, although epigenomic mechanisms are of great interest, they do not contribute to the heritability of adiposity or obesity except when the epigenomic signature at a given chromatin site persists across generations. 23 Major defects in single genes (generally homozygotes for recessive alleles) in syndromic and nonsyndromic cases account for >5% of severe obesity cases with an early age of onset. [24] [25] [26] Thus far, at least 10 genes have been causally implicated in congenital generalized lipodystrophies and familial partial lipodystrophies. 27 These single-gene cases have helped delineate some of the biological mechanisms contributing to positive energy balance and the risk of obesity.
There is also a genetic component to the common form of pediatric obesity; however, the exact magnitude of the heritability levels of traits such as BMI, adiposity or risk of obesity remains a matter of debate. What is particularly important for the risk of pediatric obesity is the narrow-sense heritability, that is, the proportion of the trait variance that can be accounted for by additive genetic effects. In humans, this is a difficult parameter to quantify. The simplest approach is to derive the heritability coefficient from the regression of offspring on their parent's phenotype. 28 Heritability levels derived from this approach are markedly lower than those obtained by other methods, particularly those based on the comparison of monozygotic and dizygotic twins raised together or apart. The latter coefficients typically include not only additive effects, but also dominance, gene-gene interaction and gene-environment effects, and such heritability coefficients are referred to as broad-sense heritability. The difference between narrow-and broad-sense coefficients can be substantial, and this has considerable implications for our understanding of obesity genotypes.
Based on parent and offspring data, it is not clear yet whether the familial risk of obesity, as assessed by the number of parents who are obese and the severity of their obesity, is stronger during infancy and early childhood as opposed to adolescence and early adulthood. What is clear is that the offspring birth weight is influenced by both maternal and paternal birth weight, as evidenced by a large Norwegian study of >67 000 mother-father--child trios, in which the mother birth weight-baby birth weight correlation (r = 0.23) was higher than the father birth weight-baby birth weight correlation (r = 0.13). 29 It is also increasingly recognized on the basis of relatively large cohort data that the mother-child correlation for BMI is slightly higher than the father-child coefficient, although the difference is small. 30 The search for the DNA variants that explain human variation in adiposity and the risk of obesity is ongoing. Thus far, about 60 single-nucleotide polymorphisms (SNPs) have been found to be associated with obesity traits at a genome-wide significance level (P ⩽ 5 × 10 -8 ). 31, 32 Three observations can be made based on these early results. First, the SNPs shown to be associated with obesity traits in adults are generally replicated in children and adolescents. Second, the new SNPs that are progressively being discovered have small effect sizes, and it takes an increasingly large sample size to be able to uncover them. Third, the fraction of the heritability accounted for by the aggregate of these SNPs remains small when conventional models of analysis are used. However, the missing heritability may not be as large as currently estimated if the more accurate approach of using narrow-sense heritability as the denominator instead of the broad-sense coefficient is used. 33, 34 Moreover, the genetic variance accounted for by SNPs may in fact be much larger when the genome-wide association data are analyzed under a different set of assumptions. 35, 36 Little has been reported on gene-gene interactions and their impact on the risk of human obesity. However, research on model organisms, such as yeast, strongly suggests that such interactions are likely having a significant role in trait variance. 37 In contrast, there is a growing body of evidence on gene-behavior interactions and their influences on adiposity and risk of obesity. Controlled intervention studies with pairs of monozygotic twins have strongly suggested that there are powerful geneoverfeeding 38 and gene-caloric restriction 39 interaction effects. In a 2010 study, Li et al. 40 estimated that a physically active lifestyle was associated with a 40% reduction in the genetic predisposition to obesity, as estimated by the number of risk alleles at 12 genome-wide association study-identified SNPs. In a very large study of the same question (N = 218 166 adults), the true reduction in risk was estimated to be on the order of 27%. 41 Studies on gene-nutrient interactions have also been reported. 42 To date, most studies on gene-behavior interaction effects have been based on observational cross-sectional or longitudinal data. These designs allow for large sample sizes, which is a fundamental condition for the detection of gene-behavior interaction effects. However, it would be more productive in the future to favor intervention studies in which the targeted behavior is systematically manipulated in order to remove the effects of confounders as much as possible and to reveal to what extent DNA sequence differences modulate the response to a change in behavior.
Although it may appear that little progress is being made on our understanding of the genetics of pediatric obesity, foundations are being laid for solid progress to be achieved in the coming decade.
ADIPOSE TISSUE DEVELOPMENT AND EPIGENETIC EFFECTS ON PEDIATRIC OBESITY
Adipose tissue is a primary target in our understanding of pediatric obesity. It undergoes pronounced developmental changes during fetal, neonatal and postnatal life that have the potential to determine an individual's lifetime adiposity and susceptibility to obesity. 43 Fat cell number increases with obesity from the earliest stage of infancy at which such measurements can be made, 44 persisting into adulthood. 45 The important impact of accelerated growth in early life is exemplified by the recent finding that in some rare genetic mutations that result in obesity, the metabolic phenotype is only apparent in early life (for example, for kinase suppressor of Ras 2). 46 It is now recognized that there are three types of adipose tissue: brown adipose tissue (BAT), beige (or brown in white) and white, each having different molecular markers that can be depot specific. 47 BAT is the least abundant fat in the body but is characterized as possessing the unique uncoupling protein 1, which has the capacity to generate 300 times more heat than any other tissue. 48 This occurs as a result of the free flow of protons across the inner mitochondrial membrane without the need for adenosine triphosphate synthesis, resulting in the rapid dissipation of chemical energy as heat. 49 Adipose tissue is one of the last tissues to appear in the fetus and BAT in particular has the essential feature of enabling the newborn to effectively adapt to cold exposure in the extrauterine environment. 43 A major factor determining adipose tissue function at birth is maturation of the hypothalamic-pituitary axis, which in small mammals only matures after birth, 50 with the result that thermogenesis in BAT does not commence until at least 1 week after birth. 51 Significant depots of BAT are present both around central organs such as the kidney and heart and also in the neck or supraclavicular region, 52 for which the latter region is the major depot. This is a primary site of thermogenesis that in childhood is influenced by BMI and ethnicity. 53 The extent to which these BAT depots are replaced by white adipose tissue or are transformed to a mix of beige and white adipocytes remains a current focus of academic debate. 54 These processes can be manipulated by environmental challenges to the fetus and/or neonate, which offer the potential to promote BAT function in the newborn as well as into later life. 55 The potential influence of maternal body weight and glycemic status on BAT remains to be described, 56 as does the substantial change in dietary and activity patterns over the past two decades, coincident with the obesity epidemic. 57 To date, the main processes in adipose tissue considered to be most strongly influenced by epigenetics relate to the actions of microRNAs 58 and long noncoding RNAs in the regulation of adipogenesis. 59 Fat depots have their own specific gene expression profiles 60 as well as developmental growth trajectories, 61 which currently do not appear to be driven by epigenetic changes. 62 Neither examining methylation profiles in blood nor looking at fractional changes in methylation of a gene provides many insights into obesity and related disease processes. 63, 64 It is also apparent that the impact of pediatric obesity is strongly influenced by gender, 65 with evidence that females are apparently being protected from the adverse effects of excess adiposity on a range of metabolic processes including inflammatory responses within the kidney. Advances in our ability to understand tissue-or depot-specific roles of fat together with its impact on whole body energy regulation 67 will be critical in developing effective early life strategies designed to prevent obesity. To this end, a technique of thermal imaging has been developed to be able to quantify potential changes in BAT activity throughout the life cycle in freeliving subjects. 68 We are now beginning to further explore the impact of other factors on BAT function including diet and genes. 69 There is now a new opportunity to both quantify and manipulate BAT development in early life in order to not only promote survival of the newborn but also to potentially prevent excess adiposity in later life. 70 
THE INTRAUTERINE ENVIRONMENT AND PEDIATRIC OBESITY
Based on the concept of developmental programming, that is, that environmental events can reset physiological development of the embryo and fetus, pre-pregnancy overweight and obesity in women of reproductive age is a significant risk factor for pediatric obesity. In the United States, 32% of reproductive age women are obese (BMI ⩾ 30 kg m ) and 56% are overweight or obese (BMI ⩾ 25 kg m -2 ).
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In overweight and obese women, between one-half to two-thirds have excessive weight gain during pregnancy, which is a significant risk factor for postpartum weight retention and increased risk of obesity in a subsequent pregnancy. 72 Concurrently, there has also been an increase in pediatric obesity with 12.3% of children and adolescents from 2 to 19 years of age having a BMI ⩾ 97th percentile. 16 An increase in weight has been observed even at birth, with a mean 114 g increase in birth weight from 1975 through 2005 in one US city. 73 The potential impact of this increase in birth weight on body composition is unknown but greater fetal adiposity at birth has a significant positive correlation with childhood obesity. 74 At birth the human neonate has between 12 and 18% body fat depending on the methodology used to estimate body composition, and as detailed above, this will compromise a combination of BAT, beige and white adipose tissue. 47 Fetal fat mass represents almost 50% of the variance in birth weight at term. 75 There are multiple factors associated with neonatal adiposity, with higher pre-pregnancy BMI and gestational weight gain being the most frequently cited. 72 Maternal pre-pregnancy BMI is the stronger correlate in overweight and obese women, whereas excessive gestational weight gain accounts for more of the variance in normal weight women. 76 Both higher maternal glucose and lipids have also been associated with fetal/neonatal adiposity. 77 Nutrient availability for feto-placental growth is a function of the metabolic alterations that occur during pregnancy. There is a 50-60% decrease in maternal insulin sensitivity during pregnancy primarily affecting maternal carbohydrate and lipid metabolism. 78 Both nutrients have a significant correlation with fetal growth and adiposity. 79 This decrease in insulin sensitivity appears to be related to increased inflammation affecting the post-receptor signaling pathways in skeletal muscle and adipose tissue. 80 The meta-inflammation of pregnancy is related to cytokines in both maternal adipose tissue and placenta. 81 There is evidence for changes in gene expression in placenta and maternal adipose tissue early in the first trimester of pregnancy 82 before any significant physiological adaptations. This may account, in part, for the relative lack of success of lifestyle interventions during later pregnancy designed to prevent excess maternal weight gain, as well as for clinical observations that maternal pre-pregnancy BMI remains a strong correlate of fetal growth and adiposity. Therefore, planning of pregnancy, including prior optimization of maternal weight and metabolic condition, offers a safe means to initiate the prevention rather than treatment of pediatric obesity.
MATERNAL NUTRITION AND DEVELOPMENTAL PROGRAMMING OF OBESITY IN OFFSPRING
The 'developmental origins of health and disease' hypothesis has highlighted the link between the periconceptual, fetal and early infant phases of life and the subsequent development of adult obesity and related metabolic disorders. One interpretation of this relationship is that the fetus makes 'predictive adaptations' in response to intrauterine cues, resulting in permanent adjustments in homeostatic systems to aid immediate survival and improve success in an adverse postnatal environment. However, inappropriate interpretations of prenatal cues or changes to that immediate environment may result in a mismatch between 'prenatal predictions' and later life experiences. As a result, these adaptations, known as predictive adaptive responses, 83 ,84 may ultimately be disadvantageous in postnatal life, leading to an increased risk of chronic diseases in adulthood and potentially a cycle of disease transmission across generations. Whether such a concept is applicable to a fetus that grows with an excess intrauterine environment and is then similarly exposed to plentiful nutrition postnatally remains to be clarified.
Using this type of conceptual framework, it is not surprising that at both extremes of the maternal nutritional spectrum, similar phenotypic outcomes are observed in offspring. Both maternal under-and overnutrition lead to increased adiposity and related metabolic disorders in offspring, which in animal models, are exacerbated in the presence of a postnatal high-fat diet. A number of animal studies have now shown that the effects of developmental programming on metabolic disorders may also manifest in future generations via either the paternal or maternal line without further suboptimal environmental exposures. 85 It has also been shown that, at least in experimental models with rodents, developmental programming of metabolic disorders in offspring is potentially reversible by nutritional or targeted therapeutic interventions during critical periods of developmental plasticity. For example, neonatal administration of the glucagon-like peptide 1 analog Exendin-4 can ameliorate the consequences of fetal growth restriction induced by uterine artery ligation, whereas pre-weaning administration of either leptin or growth hormone can reverse some of the metabolic abnormalities in offspring associated with reduced birth weight induced by more severe maternal undernutrition. [86] [87] [88] There is also an increasing interest in the role of epigenetics in developmental programming of obesity and related metabolic disorders. For example, Exendin-4 has been shown to increase histone acetylase activity and reverse epigenetic modifications that silence Pdx1 in the pancreas of growth-restricted rats. 89 It has also been shown that the effects of neonatal leptin treatment on gene expression and methylation status of some hepatic genes in adulthood are directionally dependent on the animal's nutritional status in utero. There are also data from rodents suggesting that methyl donors including folic acid, glycine and choline may have beneficial effects in offspring following imbalanced maternal nutrition, particularly as it relates to cardiovascular outcomes. [90] [91] [92] [93] In the setting of maternal obesity, dietary intervention and exercise have both been reported to have beneficial effects on offspring metabolic outcomes in animal studies in which fetal overgrowth does not occur. 94, 95 However, leptin administration to rodent offspring of mothers fed a standard rodent laboratory diet may elicit an adverse phenotype in males. 96 Translation of the preclinical findings to the clinical setting remains a clear challenge, as whether comparable effects are seen in large-for-date offspring and/or species born after a long gestation with a mature hypothalamic-pituitary axis has yet to be established.
MATERNAL WEIGHT GAIN AND PEDIATRIC OBESITY
The amount of weight gained during pregnancy is highly variable among women, with the majority of the variance, especially the increase in weight gain, being accounted for by increases in fat mass. 97 Globally, it was the issue of undernutrition that spurred the first international guidelines for weight gain in pregnant women in 1990. However, with the increased prevalence of obesity in reproductive aged women and the observation that many women were exceeding the previous Institute of Medicine (IOM) recommendations, the IOM reconvened and revised the guidelines in 2009. 72 It is recommended that to prevent adverse maternal and infant outcomes, normal weight women limit total weight gain in pregnancy to 11.5-16 kg (25-35 lbs), overweight women to 7-11.5 kg (15-25 lbs) and obese women (all classes) to 5-9 kg (11-20 lbs). 98 Weight gain in pregnancy is the result of accrual of water, protein (fat-free mass) and fat in the fetus, placenta, uterus, blood, amniotic fluid, mammary gland and maternal adipose tissue. The majority of the weight gained in excess of the IOM guidelines is deposited in maternal adipose tissue; however, limited data are available on changes in adipose tissue distribution. These studies show that in women with a normal pregravid BMI, the majority of the adipose tissue is deposited in the subcutaneous depots of the hips and thighs, 99, 100 but some visceral fat is accumulated in late pregnancy. 101 However, obese women, who have more subcutaneous fat before conception, tend to accumulate more visceral fat. 99 Understanding how fat is deposited in maternal tissues during pregnancy is important because the metabolic and inflammatory characteristics of fat stored in different depots may contribute to undesirable metabolic outcomes in pregnancy (for example, gestational diabetes, dyslipidemia and hypertension) and risk for a more rapid onset of obesity-related diseases (for example, type 2 diabetes).
As is the case with non-pregnant women, the main determinants of weight gain in pregnant women are related to energy balance, with energy intake, energy metabolism and physical activity probably all having roles. Not surprisingly, irrespective of maternal BMI, energy intake was~900 kcal day -1 higher in women exceeding the IOM recommendations compared with women with appropriate weight gain. 102 The role of specific macronutrient intake has not been widely studied, while the change in metabolic rate through pregnancy is proportional to the changes in body composition indicating that a resetting of energetic efficiency does not explain excess gestational weight gain. 102 Average weight gain in pregnancy, across all BMI categories, has increased over the last four decades from 10 to 15 kg (22-33 lbs). 103 The most recent report from the CDC shows that >48% of all women exceed the 2009 IOM guidelines for appropriate weight gain during pregnancy. 98 Excess gestational weight gain in the 2011 report was 38% for normal weight women and was 1.5 times higher in overweight and obese women at 59% and 56%, respectively. The prevalence of excess gestational weight gain within pregravid BMI categories has not shifted in the past decade, however, the number of women entering pregnancy as either overweight or obese has increased significantly from 30% in 1983 to 54% in 2011. As overweight and obese women are more likely to exceed the IOM guidelines, the prevalence of excess gestational weight gain can be forecast to continue to rise.
Excess weight gain during pregnancy is associated with a number of complications, including preterm birth, 104 infants born large for gestational age (birth weight ⩾ 90th percentile) 105 and childhood obesity. 106, 107 Although pregravid obesity is the strongest predictor of obesity and metabolic dysfunction in children, 74 weight gain during gestation is emerging as another critical predictor of childhood obesity. For example, data from the Southampton Women's Study show that children born to women with excess gestational weight gain irrespective of BMI, had greater adiposity, but within the normal range, at birth and 4-6 years of age. 108 Historical studies shown that adult offspring born to mothers with excess gestational weight gain have a higher percent body fat and waist circumference, [109] [110] [111] [112] but this has yet to be related to increased metabolic disease. Possible mechanisms linking excess gestational weight gain and large for gestational age offspring include gestational diabetes, and/or, metabolic adaptations to excess maternal adiposity that is reflected in raised pregravid BMI and maternal plasma leptin concentrations. 111 Given the available evidence, it is important to manage maternal obesity and optimize gestational weight gain by intervening before and during pregnancy, especially as two-thirds of women have either inadequate or excessive weight gain in pregnancy. This is clearly a significant challenge as intervention studies have yet to yield consistent positive effects on gestational weight gain and in turn improved maternal and infant outcomes including a reduced prevalence of pediatric obesity.
BREASTFEEDING AND PEDIATRIC OBESITY
The American Academy of Pediatrics recommends exclusive breastfeeding for all infants for approximately 6 months, followed by the introduction of complementary foods while continuing to breastfeed until at least 1 year of age. 113 This recommendation is due to the many benefits of breastfeeding, that could include the prevention of pediatric obesity, as a World Health Organization meta-analysis of 33 studies examining breastfeeding and pediatric obesity 114 indicates children who were breastfed were less likely to be overweight or obese as compared with those who never breastfed (pooled odds ratio of 0.78; 95% confidence interval: 0.72-0.84). This conclusion was confirmed by a more recent meta-analysis of 10 studies comparing breast-and formula-fed infants. 115 There are limitations to these epidemiological studies; most notably the problem of residual confounding, as breastfeeding is also related to other factors that influence child's weight, such as maternal BMI, education, income and smoking during pregnancy. There are several studies that have attempted to control for these variables and breastfeeding usually remains protective against pediatric obesity. Li et al. 116 examined the interaction between maternal obesity and duration of breastfeeding and weight at ages 2-14 years, although this comparison can be influenced by the reduced incidence of breastfeeding in women with a high BMI.Thirty-one percent of the children who never breastfed and had mothers with a BMI ⩾ 30 kg m -2 were overweight, compared with 6% of those children who were breastfed for at least 4 months by mothers with a BMI o25 kg m -2 . Bogen et al.
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reported a significantly lower odds ratio of 0.55 for those children who breastfed for >26 weeks, without supplemental formula, compared with those children never breastfed, even when adjusting for maternal BMI, age, education, parity, marital status, gender, birth weight and delivery method. There are several hypotheses as to why there is a protective effect of breastfeeding on pediatric obesity. First, the composition of human milk and infant formula vary greatly. Human milk contains over 100 bioactive components and many, such as adiponectin, leptin and ghrelin, have effects on appetite regulation, metabolism and energy balance. 118 In addition, the protein concentration of infant formula is higher than breast milk. 119 This may contribute to a more rapid weight gain in the first year of life but whether this is associated with greater adiposity is yet to be determined.
Another reason for the increased risk of obesity among formulafed infants may be due to the mode of delivery of the milk. For example, it has been postulated that receiving formula from a bottle may result in overfeeding and may diminish the infant's ability to self-regulate energy intake. 120 However, there has been a steady increase in the use of breast pumps and feeding expressed breast milk in a bottle to the infant. Li et al. 121 analyzed data from the Infant Feeding Practices Study II and reported that for a small number of infants (that is, 13 out of a total study group of 1899) receiving breast milk only from the bottle gained 89 g more per month during the first year of life compared with infants fed only at the breast. Fifty-eight percent of mothers reported that their infants always or most of the time emptied the bottle of formula or breast milk. 122 Infants who emptied bottles in early infancy were 69% more likely to have excess weight (weight for age >1 z-score) after 6 months of age, but whether fat mass is affected in the long term is not known.
In conclusion, breastfeeding may be a preventive factor against pediatric obesity, whereas bottle feeding may result in lack of selfregulation of appetite and increased rate of weight gain. In addition, formula feeding may increase the prevalence of obesity because of the higher protein concentrations, increasing insulin levels, stimulating fat deposition, and resulting in more rapid growth. 120 Formula also lacks many bioactive compounds, including some that regulate appetite and metabolism. 118 Based on current evidence, public health professionals should promote breastfeeding for its many benefits to mothers and children, including the protective effect against pediatric obesity. Bottlefeeding mothers should be taught the cues of infant hunger and satiety, allowing the infant to develop self-regulation of milk intake.
EFFICACY AND EFFECTIVENESS OF PHYSICAL ACTIVITY AND NUTRITION INTERVENTIONS IN PEDIATRIC OBESITY
To reduce the prevalence of pediatric obesity, efficacious research findings need to be translated into practice. Translation enhances implementation of evidence-based interventions (EBIs) into evidence-based practice in clinical and community settings. As a first step, EBIs are generally tested within efficacy trials, focusing on evaluating an intervention under 'ideal' conditions, where a high degree of control over implementation is exercised to maximize internal validity. [123] [124] [125] The next step is to evaluate EBIs in real-world settings (that is, health care, community and so on) [123] [124] [125] using effectiveness trials to assess enhanced external validity and sustainability. 124, 125 A key challenge in translation is balancing EBI fidelity with acceptability within clinical and community settings. 123, 124 Decreases in EBI fidelity reduce ability to achieve expected outcomes. However, failure to achieve acceptability of an EBI by providers and/or consumers may prevent the translation of EBI into evidence-based practice. 124 To assist with translation, the US Preventive Services Task Force (USPSTF) identified effective behavioral pediatric weight management programs considered to be comprehensive, medium-to-high intensity (26-75 h of program contact) and primary-care relevant. 126 Comprehensive programs were identified as including a dietary and physical activity component and using behavioral modification strategies. These programs significantly reduced BMI (-1.9 to -3.3 kg m -2 ) and improved metabolic outcomes in overweight and obese children. Although these programs were considered to be primary-care relevant, the USPSTF concluded that because of the content of the programs and amount of treatment contact, these programs would be feasible only in specialty settings.
There are several recommendations regarding modifications in intervention intensity, which include decreasing frequency and duration of contact, narrowing agent of change, decreasing comprehensiveness of dietary goals, focusing on dietary or leisuretime activity goals, and reducing number and/or use of behavioral strategies 127, 128 have been proposed to overcome translational challenges in pediatric obesity. 128 As these modifications impact EBI fidelity and may reduce ability to achieve previously reported weight improvements, identifying clinically relevant BMI reductions is important for ascertaining modification effectiveness. EBIs for pediatric weight management have produced a reduction of approximately -1.0 in standardized BMI (zBMI). 129 However, what reduction is needed to improve metabolic outcomes in children to provide clinically relevant results? Although little research has examined this question, two studies suggest that a zBMI decrease of -0.13 to -0.25 is needed to improve metabolic outcomes. 130, 131 Several studies have examined recommended modifications to EBIs for pediatric weight management (Table 1) . One investigation reduced intensity of contact using a guided self-help approach. 132 The guided-self-help condition provided all components of the comprehensive, behavioral interventions, which was delivered in 12 face-to-face sessions, totaling approximately 4.5 h of contact time, which was supplemented with parent and child self-help manuals. At intervention end, there was a significant difference in reduction of zBMI favoring the guided self-help condition. Another investigation reduced intensity of contact and narrowed the agent of change and decreased the comprehensiveness of the dietary goals. 133 In this 4-month investigation, the behavioral interventions were delivered in 12 face-to-face sessions, totaling 18 h of contact time. At treatment end, the parent-only intervention had a greater reduction in zBMI than the wait-list control, which was the only significant difference found between conditions. Further modifications were examined in two trials that reduced intensity of contact combined with narrowing agent of change, decreasing comprehensiveness of dietary goals, and targeting dietary or physical activity/sedentary behavior goals. 134 Each trial had two behavioral, family-based interventions delivered to the parent only, but differed in diet and leisure-time activity goals. Trial 1 focused on changing two dietary behaviors, while Trial 2 examined changing one dietary and one leisure-time activity behavior. Both trial interventions were delivered in 8 face-to-face sessions, totaling 6 h of contact time. At 12 months, both trials found a significant reduction in zBMI (Trial 1 = -0.12; Trial 2 = -0.16), with no difference between the three conditions in each trial.
One cluster randomized controlled trial (RCT) examined all recommended intensity modifications. 135 This investigation included 10 pediatric practices randomized to either usual care or a 12-month Chronic Care Model intervention. The 475 children in the trial were aged 2-6 years and ⩾ 85th BMI percentile. Intervention was delivered to the parent only, used motivational interviewing and focused negotiation skills for behavior. The intervention was focused on changing a dietary or leisuretime activity behavior, and was provided in four face-to-face sessions, and three phone calls with the parents only, totaling 2.5 h of contact time. At 12 months, the reduction in zBMI was -0.05, with no difference between the conditions. In summary, to assist with translation, many methods that reduce treatment intensity have been examined to increase acceptability. Critically increasing the number of intervention modifications reduces the ability to reduce BMI. Thus, research is needed to identify the effective components of family-based, comprehensive behavioral interventions that can be delivered at the lowest contact intensity to improve pediatric weight status of a magnitude that is clinically relevant.
FAMILY-BASED PEDIATRIC OBESITY TREATMENT PROGRAMS
Childhood represents an ideal time for lifestyle interventions, 136 as lifestyle behaviors in youth are not yet ingrained and intervention can often occur before the onset of medical comorbidities that could complicate treatment. Intervening in childhood further capitalizes on the potential for height growth, such that small reductions in weight can have a significant, positive impact on obesity and related disease risk. 137 Finally, parental involvement can be harnessed to provide ongoing support for healthy behavior change 138 and demonstrate the largest effects. 139 Family-based behavioral treatment is a behavioral weightcontrol intervention that concurrently targets children who are overweight and their parents. 136, [139] [140] [141] [142] [143] [144] It focuses on successive changes using family support and utilizes strategies such as selfmonitoring, reinforcement and stimulus control to facilitate Evolving science of pediatric obesity PT Katzmarzyk et al Evolving science of pediatric obesity PT Katzmarzyk et al behavior change. Multiple meta-analyses confirm that familybased behavioral treatment should be considered a first-line approach to treatment. 126, 136, 139, [144] [145] [146] Based on this evidence, the USPSTF has given a grade B recommendation (there is high certainty that the net benefit is moderate or there is moderate certainty that the net benefit is moderate to substantial) for children who are overweight and obese to receive specialty treatment of moderate-to-high intensity that includes dietary, physical activity and behavioral counseling components. 147 Despite successful weight loss during treatment of children, maintaining these effects over the long term remains a challenge. Weight loss maintenance interventions (delivered after an initial family-based behavioral treatment weight loss phase) demonstrated improved short-term efficacy of weight loss, with social facilitation maintenance (SFM) treatment yielding the strongest effects. 148 Although children sustained their levels of weight loss while in weight maintenance treatment, once contact ceased, some weight regain occurred. Nonetheless, there was an overall 'net effect' of weight maintenance treatment, even 20 months after all treatment cessation. Therefore, weight maintenance interventions that incorporate a socioenvironmental approach (targeting behaviors across social and environmental contexts) with the continued use of self-regulating behaviors may improve long-term weight outcomes in children.
Although the previous trial compared maintenance treatment with a no maintenance treatment control condition, the study design precluded evaluating whether specialized treatment content or continued contact contributed to maintenance effects. As a result, the SFM treatment was enhanced (SFM+), and is predicated on learning theory research, which suggests that previously learned behaviors and newly learned behaviors exist simultaneously within a behavioral repertoire, rather than new learning replacing old learning. 149 In the context of obesity, weight regain is common, as environmental cues tend to trigger responses from previous learning (that is, unhealthy weight behavior). However, this finding also predicts that if new learning (that is, healthy weight behaviors) is practiced and reinforced intensively and across multiple contexts, the chance for relapse decreases. Accordingly, SFM+ utilizes a supportive, socioenvironmental approach by deliberately targeting the practice of new weight maintenance behaviors, including self-regulatory behaviors specific to weight loss maintenance, across contexts.
Biosimulation projections suggested that SFM+ is promising 150 and this treatment is currently being compared with a credible health education program, matched for time and attention, in a large-scale RCT. Moreover, emerging research supports the importance of intervening on each socioenvironmental level (that is, individual, family, peer and community). For example, appetitive traits like food reinforcement and impulsivity influence response to behavioral treatment, 151 parent weight loss predicts child weight loss, 152 peers and friends increase overweight/obese youths' motivation to be physically active, 153 and the built environment impacts weight maintenance. 154 Current research is now focused on (1) optimizing the duration and intensity of family-based weight loss maintenance treatments, (2) examining the mediating influences of peer interactions, social problems, parent weight loss, and feeding practices on children's weight loss and weight maintenance and (3) evaluating cost-effective delivery models that can be readily scaled for widespread dissemination. Continued attention to identification and early intervention remains a priority, particularly regarding opportunities to tailor interventions specific to individuals' and families' risk and symptom profiles. Future efforts should target integrating family-based interventions in routine clinical practice, increasing training and credentialing programs for providers, and advocating for third-party reimbursement for pediatric obesity care.
MOBILE-HEALTH APPROACHES TO TREAT PEDIATRIC OBESITY
Mobile and wireless health (mHealth) technologies have developed at an exponential pace in recent years. For example, lowcost, real-time technologies to assess and/or intervene on disease, movement, images, behavior, social interactions, environmental toxins, hormones and other physiological variables, have made remarkable advances in the last decade because of increased computational sophistication, as well as reductions in size and power requirements. 155 In particular, smartphones have many capabilities that can be harnessed for promoting health. 156 Beyond basic capabilities for two-way communication (that is, voice or SMS), many mobile phones have built-in cameras, gigabytes of storage, an Internet browser, global positioning systems support, built-in accelerometers, connectivity to WiFi, and wireless communication with external devices and to outside networks via Bluetooth (for example, heart rate monitors, external accelerometers). In addition, mHealth can also take advantage of stationary data that can be correlated with movement through global positioning systems. In the past, behavior could only be measured by subjective observation and self-report, but today's technologies provide opportunities to passively capture a digital 'footprint' that catalogues a person's everyday behaviors, contexts and even states. Data streamed from a broad variety of sources, for example, sensors, social media, pictures and videos, location, purchase transactions, applications and Internet use, can, when aggregated, provide an in-depth view of the person as they interact with the world around them. Technologies are emerging for overarching, in situ measurement of behavior and intention using multi-modal sensing sources. These new mobile technologies offer heretofore unimagined opportunities for tracking and intervening on obesity-related behaviors (for example, physical activity, healthful eating, sleep and stress) and important physical outcomes (for example, weight and body composition).
The promise of mHealth is based on the premise that mobile technologies can allow us to develop behavioral monitoring and change systems that are personalized, adaptive and delivered in real-time. [157] [158] [159] Available research suggests that immediate and contextualized feedback is superior to traditional approaches to promote behavior change 160 as well as improve learning. 161, 162 These technologies also enhance the possibility of scaling surveillance, prevention and intervention efforts in ways that have been unthinkable with conventional face-to-face programs. Further, these devices have the ability to capitalize on small, but frequent intervention doses at timing that is optimized for the individual user. Wearable and deployable sensors and smart phones can provide rich, temporally dense contextualized data that allows for the personalization of instantaneous feedback, ensuring appropriate response, messaging, timing and a dose that is adaptive. 163 More specifically, these adaptive technologies can be set to prompt for answers to questions or deliver intervention content based on current behaviors, behavior changes and locations, at random or in response to particular events. 157 Early and ongoing uses of mobile technologies to intervene on obesity-related behaviors in youth include SMS text-messaging and Ecological Momentary Interventions. 164, 165 Although results are mixed, in general, SMS text-messaging interventions, compared with paper diaries, appear to be effective at promoting increased adherence to self-monitoring of physical activity, 165 and tailored SMS messages appeared to help improve awareness of weight management 166 in pediatric populations. SMS has also been used to successfully reduce dropout in pediatric obesity interventions. 167 However, these types of interventions do not harness the true capabilities of mHealth technologies, such as ubiquitous measurement and real-time feedback. 168 Newer systems are moving toward real-time data collection. [168] [169] [170] [171] [172] [173] These systems typically provide visual feedback to the user: for example, UbiFit, which uses a display of a garden that users can quickly glance at to convey information on physical activity, 169 Fish'n'-Steps where the growth and happiness of a virtual fish is tied to daily step count 166 or MOPET, which uses a virtual trainer to provide motivation and advice. 172 Others incorporate social networking to connect users and encourage physical activity through competition or social support. 164, 166, 167, 171, 173 A few mobile systems that involve some sensing capabilities, including gDitty (now Zamzee) 174 and ChickClique, 173 have been developed for children and adolescents; however, these require manual upload of data and therefore cannot be used for real-time, databased feedback. mHealth has yet to reach its full potential in pediatric obesity. 168, 172 KNOWME Networks for Hispanic youth is one of the first interventions to take advantage of a combination of ubiquitous and active data collection and real-time feedback.
169,171 KNOWME is a suite of wireless, wearable sensors that monitor behavior and interface with a mobile phone to collect, store, analyze, display and transmit data to a secure web interface in real-time. KNOWME supports just-in-time adaptive interventions that respond to moment-by-moment contextualized behaviors. Development of the product included a youth advisory team made up of 20 minority youth (ages 12-17 years) that met at each design phase to determine wearability, messages and feedback, and interface design. Personalized algorithms using sensor and phone data streams were developed for each advisory member that recognized seven activities (lying down, sitting, standing, slow walk, brisk walk, active game play and running) with an overall accuracy of 94%. 169, 170 To examine wearability and test the web interface, 12 overweight Hispanic youth, (five females, 14.8 ± 1.9 years old, BMI percentile 97 ± 3) wore KNOWME for 2 weekend days. Participants wore KNOWME for 11.4 ± 2.0 h per day, sent a mean of 8 SMS messages to the research team per day and received a mean of 9 SMS messages in return per day. To test whether wearing KNOWME for a weekend could increase physical activity and decrease sedentary behavior, 10 Hispanic youth (mean age 16.3 ± 1.7 years, mean BMI percentile 97.2 ± 4.4, 50% female) wore an accelerometer for a 2.5-day weekend to determine baseline activity levels. Within 3 weeks from baseline, participants wore KNOWME for the full 2.5 days. KNOWME sent time-stamped participant activity data to a secure website, which displayed minute-to-minute participant data (physical activity, sensor functioning) and refreshed every 10 min. If a participant was sedentary for over 2 h, KNOWME automatically generated a 'MOVE!' message, and a research team member initiated an SMS conversation prompting the participant to be active. Sedentary behavior was significantly lower during KNOWME wear as compared with baseline wear (~171 min, P o0.1). Physical activity increased by 1.5 min day -1 (P o0.09) in this group that showed o 1 min of moderate-to-vigorous physical activity per day at baseline. Approximately 75 SMS messages were sent between researchers and participants (43% from participants) during the weekend. Lagged mixed regression analysis showed that prompts sent to participants were associated with an increase in physical activity (Po 0.0001) in the following 10-min period. SMS prompts sent to participants were post-hoc coded using motivational interviewing principles into four message types: affirmation, suggestion, neutral and prompting question. When prompting question messages were sent to participants, physical activity in the following 10-min period was significantly higher (2411 accelerometer counts) than when messages of that type were not sent (Po 0.01). These findings indicate that using a mobile suite to collect real-time data can increase physical activity and decrease sedentary behavior in overweight Hispanic youth. Further, prompting adolescents to engage in physical activity with reflective SMS messages is a potentially effective intervention approach for overweight Hispanic youth. The next step for KNOWME is scaling up.
In summary, mHealth interventions show promise for the prevention and treatment of pediatric obesity, including gaming and entertainment experiences, new forms of real-time adaptive feedback and social networks. 158 EXERGAMING AS A STRATEGY TO TREAT PEDIATRIC OBESITY Screen-based entertainment that is highly popular among children may provide an innovative tool to treat pediatric obesity. 175 Exergaming, which is video gaming that involves gross motor movement, is now recognized as a viable physical activity option by leading scientific and health organizations, including the American Heart Association and the Presidential Active Lifestyle Award. Systematic reviews and meta-analyses indicate that exergaming can reach criteria of moderate-intensity activity. [176] [177] [178] Eighteen studies that examined youth exergame play found an increase in youths' energy expenditure on average 222 ± 100% and increase in heart rate on average 64 ± 20%. 177 Importantly, exergaming that involved lower body movement produces higher energy expenditure than exergaming that used just the arms. 176 In addition, playing with or against a partner rather than alone induces higher energy expenditure. 175 Group-based exergame programs supervised in a laboratory or school setting have shown promising results for improving behaviors and health outcomes. One key contributing factor is friend participation and social interaction, which encourage sustained exergame play. For instance, a 20-week RCT assigned overweight and obese adolescents to cooperative exergame play (that is, play in a team to earn points), competitive exergame play (that is, play against a partner to win) or a control condition. 179 Those adolescents who played cooperatively (approximately 20 h over 20 weeks) lost significantly more weight compared with the control group, for a difference of 2.6 kg. In a separate study, adolescents who played a tennis exergame against a peer expended more energy than those who played alone, and the energy expended in social play was comparable to energy expended during a beginner's tennis lesson on a tennis court. 180 The Exergaming for Health group weight loss program included 10 1-h gaming sessions over 10 weeks and found a significant reduction in BMI z-score, increased weekly exercise of 2 h per week, and an 84% retention rate among 48 overweight and obese 8-16 years old. 181 Finally, a study of 27 children aged 9-12 years found that those assigned to weekly multiplayer classes played twice as long and had a significantly lower dropout rate (15% vs 64%) compared with those who played only at home. 182 Despite this emerging evidence of efficacy in exergaming interventions, many interventions do not provide sufficient frequency or duration of game play to produce weight loss. In fact, a bout of exergaming may be compensated with reduced physical activity or increased energy intake throughout the day, either of which would decrease or even counteract the potential weight loss from exergaming. 183 Attenuating weight gain may be a more age-appropriate goal for overweight or obese adolescents, and this outcome was observed in four of six RCTs in a recent meta-analysis of exergames. 183 After 30 dance exergaming sessions of 40-60 min each over 10 weeks, there was no observed BMI change among obese adolescents but higher perceived competence to exercise regularly compared with a no-game control group, which may help to encourage exercise and weight maintenance. 184 Fifteen-minute bouts three times per week over 8 months did not change BMI or body fat but did enhance cardiorespiratory endurance in 208 school children, which may also contribute to weight maintenance. 185 An additional consideration in exergaming is game play in the home without a structured intervention program, which has not achieved success in changing children's body composition, largely due to high attrition and waning interest in game play. [186] [187] [188] A notable exception is a 24-week home-based exergame intervention for 322 overweight and obese 10-14 years old that observed a significant decrease in BMI (-0.24) and a significant decrease in body fat (-0.83%). 189 In addition, a 12-week dance exergame intervention in the home observed improved endothelial function and aerobic fitness among 35 overweight/obese children. 190 In summary, exergaming has been repeatedly documented as producing moderate-intensity physical activity, and several recent trials have demonstrated weight loss in structured, supervised exergaming interventions. Given the popularity and novelty of playing video games for health, exergames may equip youth with a fun option for physical activity and weight loss under the appropriate conditions.
TREATMENT OF PEDIATRIC OBESITY IN HEALTH-CARE SETTINGS
Health care clearly has a function in both the prevention and treatment of pediatric obesity. However, effective obesity intervention strategies may not fit well in traditional health-care office visits, and so it is not straightforward. To provide guidance to health-care providers, the American Medical Association, the CDC, and the Maternal and Child Health Bureau convened an expert committee to make recommendations on assessment, prevention, and treatment of child and adolescent obesity. 191 They summarized current publications on behaviors that are either associated with healthier weight (cross-sectional) or lead to improved weight when adopted. Unfortunately, the limited evidence focused on the target patient behaviors, and seldom addressed the effectiveness of the delivery of this information in the health-care office setting. The treatment committee therefore proposed a staged approach, beginning with low-intensity interventions, offered through the primary-care office and advancing to more intensive interventions with increasing use of specialized professionals and programs (Table 2) . 191 Not surprisingly, the evidence about effectiveness is more robust for the more intensive stages:
For stages 1 and 2, the science in this area is emerging. A large study of brief counseling to reduce multi-media use was not designed to improve weight, but the significant increase in the number of parents reporting media limitation a year later is a evidence that low-intensity intervention can change behavior, but effects on BMI were not assessed. 192 Two controlled studies of low-intensity interventions aimed at improving weight status in younger children in primary-care settings showed no effect on BMI at 1 year. 135, 193 Several large studies are now underway to evaluate more intensive practice-based interventions, and include (1) motivational interviewing delivered by a either a primary-care provider or more intensively by dietitians, 194, 195 and (2) collaboration between a multidisciplinary team and primary-care provider with the use of web-based software. 196 For stage 3, a Cochrane review concluded from an assessment of RCTs that 'Family based, lifestyle interventions with a behavioral program aimed at changing diet and physical activity thinking patterns produce significant and clinically meaningful decrease in overweight in children and adolescents…in the short-and longterm'. 197 Such programs need to be moderate-to-high intensity, generally weekly or more often for 3-4 months. Although programs like this could be offered through the health-care system, its current structure creates many barriers such as: insurance not always paying for obesity counseling, physicians and other health providers are usually not trained in counseling, and standard consultations are too short. An observation of primary-care providers documented that they spend only 70 s on average on diet, growth and activity counseling during well child visits, and the maximum was o 2.5 min. 198 Thus, feasibility and effectiveness of addressing the causes of obesity within medical homes needs to be addressed. . 199 However, this highly aggressive approach is not widely available, although the physiologic selection criteria used by a current NIH consortium study, which includes BMI>40 kg m -2 and physical maturity, apply to several hundred thousand adolescents. 17, 200 Access, capacity, insurance and patient preference limit the usefulness of this approach. For medication, Orlistat, which reduces absorption of dietary fat, is the single weight-control medication studied in and approved for youth aged 12 years and older. Its benefit is modest and when accompanied by diet and activity counseling, orlistat has led to a placebo-subtracted BMI difference of -0.88 kg m -2 .
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In contrast, a meal replacement program in severely obese adolescents showed no difference at 1 year when compared with conventional-restricted diet. 202 Finally, more deliberate partnerships between health-care and community and school systems are the focus of three CDCsponsored Childhood Obesity Demonstrations Projects. Each site has a different protocol, but all will engage primary health-care, schools, early childhood education sites, community centers, community health workers, as well as family within catchment areas that contain high populations of low income, racially and ethnically diverse children aged 2-12 years. 203 The results of these studies will further delineate ways that health care can effectively combat the childhood obesity epidemic.
PHARMACOLOGICAL APPROACHES TO TREAT PEDIATRIC OBESITY As behavioral interventions have shown relatively limited success among a substantial proportion of severely obese children and adolescents, 139, 142, 204, 205 there is interest in combining lifestyle modification with more intensive strategies to ameliorate pediatric Evolving science of pediatric obesity PT Katzmarzyk et al obesity. 206 Consequently, the use of pharmacologic agents is of considerable interest, although to date only orlistat, as mentioned earlier, holds Food and Drug Administration (FDA) approval to treat obesity among adolescents aged 12-16 years, and none are approved for children below age 12 years.
The classical anorexiants, such as phentermine, 207 diethylpropion 208 and mazindol, [209] [210] [211] [212] alter the release and reuptake of neurotransmitters (that is, norepinephrine, serotonin and dopamine) that impact on appetite. 213 No weight loss medication with these mechanisms of action is currently approved for pediatric use and no available data support their long-term (>1 year) safety or efficacy in pediatric populations. Only small trials, using phentermine 207, 214 or diethylpropion, 208, 215 that lasted no more than 12 weeks, have been reported in a pediatric population.
Lorcaserin is a selective 5HT2C receptor agonist that acts primarily in the central nervous system to inhibit feeding behavior. 216 Three phase III multicenter clinical trials [217] [218] [219] found that lorcaserin decreased adult body weight modestly by about 3.2 kg more than placebo 220 and improved comorbid conditions. 218, 221 No pediatric trials of lorcaserin have been reported. Bupropion 222 is an antidepressant that inhibits presynaptic reuptake of both norepinephrine and dopamine. 223 No pediatric RCTs of bupropion examining its effects on body weight have been published, although some short-term open-label studies suggest its use may be associated with small amounts of weight loss in adolescents. 224, 225 There are several older drugs for which pediatric trials exist that affect appetite primarily by increasing serotonergic release or inhibiting reuptake, 226, 227 including fluoxetine, chlorphentermine, fenfluramine and its stereoisomer, dexfenfluramine. [228] [229] [230] [231] [232] [233] None of these drugs are currently FDA-approved for weight loss and most have been removed from the US market.
Topiramate is a GABA-ergic anticonvulsant drug that was fortuitously found to cause weight loss in patients with epilepsy. When used in children for the treatment of epilepsy 234 and migraine, 235 its use was associated with 1-2 kg decrease in body weight versus placebo, a response confirmed in a limited number of open-label case series. [236] [237] [238] [239] Concerns over the impairment of cognitive function at dosages similar to those used to treat seizure disorders will likely limit its use as a stand-alone agent, 240 and to date, no controlled trials restricted to obese children or adolescents have been reported. It is also important to note that there is concern that the risk for cleft lip with or without cleft palate is increased in children born to mothers who used topiramate during pregnancy. 241, 242 Phentermine/topiramate-extended release combines low-dose phentermine with a non-standard dose of the antiepileptic medication topiramate-extended release. Placebo-subtracted weight loss in adults 243, 244 at 1 year for 15 mg/92 mg day -1 is -8.9 kg (-8.3 to -9.4), but has not undergone any randomized pediatric studies.
Sibutramine was one of the best-studied weight loss medications in adolescents, [245] [246] [247] [248] [249] [250] [251] [252] [253] [254] and when combined with behavioral therapy for 6-to 12-month periods led to -2.9 to -3.6 kg m -2 decreases in BMI, but was never approved for use in children younger than 16 years. 255, 256 The other drugs investigated all focus on glucose metabolism and/or gut function. They include glucagon-like peptide 1, which activates central nervous system glucagon-like peptide 1 receptors to reduce food intake via glucose metabolism-dependent inhibition of central cAMP-activated protein kinase. 257 A 12-week open-label crossover study of 12 extremely obese children has reported a treatment effect of -3.9 kg compared with behavioral intervention alone from exenatide, 258 and a 3-month RCT 259 in 26 severely obese adolescents found a similar effect (-3.26 kg placebo-subtracted weight loss). However, even after another 3 months of open-label treatment, BMI was reduced by only 4%.
Studies documenting the long-term safety, tolerability and efficacy of glucagon-like peptide 1 analogs in children and adolescents are still needed.
Orlistat, the gastrointestinal lipase inhibitor, is approved by the FDA for management of obesity in adolescents 12-16 years of age. 201, [260] [261] [262] [263] [264] [265] [266] The largest study 201 increase with placebo after 52 weeks. The most common adverse events were oily stools (50%), oily spotting (29%) and oily evacuation (23%); 2% of the dropouts in the orlistat group were described as due to drug-related adverse effects. 201 Although orlistat is the only FDA-approved treatment for obesity among adolescents under the age of 16 years, it appears to offer little prospect of benefit to those with severe obesity and to date, limited metabolic benefits from orlistat therapy among adolescents have been reported. 201, 262, 267 Metformin is a biguanide that inhibits intestinal glucose absorption, reduces hepatic glucose production and increases insulin sensitivity in peripheral tissues. 268, 269 It is approved for the treatment of type 2 diabetes in adults and children over 10 years of age 270 but not approved for treatment of obesity. Metformin has only modest effects on weight loss in children or adolescents. [271] [272] [273] [274] [275] [276] [277] [278] [279] [280] [281] [282] [283] [284] [285] [286] [287] Octreotide is a somatostatin analog. 288 Pediatric studies evaluating this drug for weight loss via subcutaneous injection in Prader-Willi syndrome or hypothalamic obesity suggest limited efficacy. [289] [290] [291] [292] Growth hormone stimulates lipolysis and decreases fat mass [293] [294] [295] [296] [297] and stimulates an increase in lean body mass as observed in both adult and pediatric patients with Prader-Willi syndrome to whom it has been given. [298] [299] [300] However, a review of clinical trials of recombinant growth hormone administration in patients with obesity, showed no better performance than a hypocaloric diet. 301 Effective pharmacotherapy that reverses excessive adiposity and improves obesity-related comorbid conditions in pediatric patients remains elusive. Currently, the weight management impact of available drugs has been modest. Meta-analyses of trials for weight loss in pediatric samples have shown minimal effects, and in many cases no greater than the response to behavioral interventions. 139 Even when combined with state-ofthe-art behavioral interventions, existing pharmacotherapy among adolescents has only moderate efficacy. 201, 286, 302 Current guidelines, however, include medication in their recommended approaches to treat obese adolescents. 191, 303 Unfortunately, the most efficacious medications for treating obesity have had to be withdrawn because of adverse events. However, because of the importance of the metabolic pathways involved in the regulation of energy balance, it is unlikely that any highly effective weight loss medication will be risk free. It remains to be demonstrated if the potential benefits from long-term use of anti-obesity medications for individual children will outweigh their risks.
BARIATRIC SURGERY FOR OBESITY AND RISK FACTOR REDUCTION IN PEDIATRICS
The group with the most compelling medical complications of obesity are the 4-6% with severe pediatric obesity (BMI ⩾ 99th percentile or BMI ⩾ 120% of the 95th percentile), 304 in which lifestyle modification and behaviorally based interventions have little if any effect, 139 despite being effective in moderately obese youth. 264, 305 In addition, for those who can lose some weight with lifestyle changes, maintenance of weight loss is challenging and recidivism is common. 306 In adult patients, surgical interventions for weight loss (bariatric surgery) have generally been effective for inducing a sustained Evolving science of pediatric obesity PT Katzmarzyk et al decrease in BMI, improving important health conditions and extending longevity beyond that which would be expected without the surgical intervention. 307 Thus, it is logical to consider which and how such procedures may be used appropriately in adolescents.
A variety of procedures that anatomically alter the gastrointestinal tract have been used for weight loss. The procedures result in the restriction of stomach capacity, interference with meal progression or diversion of ingested contents from one region of the gastrointestinal tract to another. 308 The most commonly used procedures for adolescents today include Rouxen-Y gastric bypass, adjustable gastric banding and the more recently introduced vertical sleeve gastrectomy. 309 Adolescents treated with Roux-en-Y gastric bypass typically experience a significant 35-37% reduction in BMI by 1 to 2 years postoperatively. 310, 311 Although definitive studies are underway, many have shown that surgery in adolescents results in improvement or resolution of numerous comorbid conditions including sleep apnea, 312 diabetes 313 and improvement in quality of life. 314, 315 Perioperative and longer term risks must be acknowledged, 309, 316 and bariatric surgery among severely obese adolescents is a viable option, 317, 318 but further research is required to determine the long-term effectiveness of this approach.
TRANSLATION TO CLINICAL AND PUBLIC HEALTH PRACTICE
This review and symposium have taken a broad approach to the problem of pediatric obesity, and evidence presented on factors related to pediatric obesity including genetics, epigenetics, intrauterine and maternal health, as well as behavioral, pharmacological and surgical interventions. Based on these discussions, the following recommendations are made with respect to translating these findings to clinical and public health practice in order to overcome pediatric obesity:
1. It is never too soon to initiate preventive efforts, and given the evidence for inter-generational and intrauterine effects on pediatric obesity, these should begin before conception, continue during pregnancy and in the early post-partum period, and sustained across these developmental windows. 2. Promoting appropriate weight gain during pregnancy with regard to the IOM recommendations should be widely disseminated and their adoption promoted. Importantly, the implications of weight loss for obese pregnant women are not understood and should be discouraged until safety data are accumulated. 3. The many benefits of breastfeeding, including a potential preventive role for pediatric obesity, indicate that it should continue to be strongly promoted. 4. Behavioral and family-based interventions show effectiveness in lowering BMI of overweight and obese children and adolescents, especially when initiated at a young age. However, these interventions demonstrate lower efficacy in cases of severe obesity, and treatment effects decrease with advancing age. Therefore, efforts that focus on preventing normal weight and overweight children from becoming obese are key to the reduction of pediatric obesity prevalence. 5. Efficacious lifestyle-based interventions for pediatric obesity need to be translated and modifications documented and tested for effectiveness in real-world settings, including adapting the role of the health-care provider in identification, treatment and/or referral. 6. Efficacy and effectiveness of approaches to pediatric obesity using novel technologies are required. Interventions that rely on mHealth solutions and exergaming are promising strategies that appear to engage and encourage healthy behavior, but more research is required.
7. Although pharmacological approaches to treat pediatric obesity are being sought, there are currently no agents available that can be recommended for use in children. There may be specific subgroups of obese children who will particularly benefit from pharmacotherapy, but again, further research on identifying predictive factors for success is needed. 8. Early evidence indicates that bariatric surgery holds considerable promise as an effective and safe approach to treat severe obesity among adolescents who are at high risk of health complications and premature mortality because of their extreme levels of adiposity. Ongoing studies will further elucidate advantages and potential risks of use of surgery in youth.
In addition to these practice-based recommendations, further research is required on all aspects of obesity prevention and treatment explored in this review, particularly the basic biology into the regulation of energy balance, particularly energy intake and metabolism in early life. Furthermore, fundamental studies are needed to establish the driving factors determining the profile of adipose tissue distribution, how it becomes individualized, and potential opportunities to intervene on these processes. Research also needs to continue on the prepregnancy and in utero determinants of adiposity in infancy and throughout the growth period. All of the above recommendations require that the power of genetics, epigenetics and developmental biology are used to address these fundamentals questions, which have the potential, if resolved, to develop the tools to prevent or treat excess adiposity at critical stages of development. 
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